View More Recent Stories

Jan 13, 2025 07:16AM Pacira Pharmaceuticals (PCRX) PT Raised to $30 at Needham
Jan 10, 2025 12:53PM Raymond James Reiterates Market Perform Rating on Pacira Pharmaceuticals (PCRX)
Jan 10, 2025 08:01AM Pacira BioSciences (PCRX) Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization
Jan 7, 2025 08:02AM Pacira BioSciences (PCRX) Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block
Dec 19, 2024 11:16AM RBC Capital's Game Changers: 'Disruptive Forces in Biotech'
Dec 3, 2024 07:30AM Pacira BioSciences (PCRX) Awarded New U.S. Patent Covering EXPAREL Composition
Nov 14, 2024 10:06AM Pacira BioSciences (PCRX) Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
Nov 7, 2024 07:42AM Pacira Pharmaceuticals (PCRX) PT Raised to $12 at Piper Sandler
Oct 21, 2024 08:00AM Pacira BioSciences (PCRX) Appoints Shawn Cross as Chief Financial Officer
Oct 3, 2024 08:04AM Pacira BioSciences (PCRX) Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
Sep 26, 2024 08:03AM Pacira BioSciences (PCRX) Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
Sep 25, 2024 08:16AM DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences (PCRX) to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders
Sep 24, 2024 09:32AM Pacira Pharmaceuticals (PCRX) PT Raised to $18 at Jefferies
Aug 13, 2024 06:06AM Truist Securities Double Downgrades Pacira Pharmaceuticals (PCRX) to Sell
Aug 12, 2024 06:52AM Pacira Pharmaceuticals (PCRX) PT Lowered to $39 at H.C. Wainwright
Aug 12, 2024 06:43AM RBC Capital Downgrades Pacira Pharmaceuticals (PCRX) to Sector Perform
Aug 12, 2024 04:05AM Raymond James Downgrades Pacira Pharmaceuticals (PCRX) to Market Perform
Aug 12, 2024 02:26AM JPMorgan Downgrades Pacira Pharmaceuticals (PCRX) to Underweight
Aug 12, 2024 02:25AM Piper Sandler Downgrades Pacira Pharmaceuticals (PCRX) to Neutral
Aug 9, 2024 03:23PM Pacira BioSciences (PCRX) Halted on Volatility, Down 12.6%
Aug 9, 2024 03:23PM Pacira BioSciences (PCRX) Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
Aug 1, 2024 03:59PM Pacira Pharmaceuticals (PCRX) PT Lowered to $30 at Jefferies
Jul 31, 2024 06:24AM Pacira Pharmaceuticals (PCRX) PT Lowered to $37 at RBC Capital
Jul 30, 2024 05:26PM Pacira Pharma (PCRX) Tops Q2 EPS by 20c; offers guidance
Jul 10, 2024 04:20PM Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL (PCRX)
Jul 3, 2024 07:16AM Piper Sandler Reiterates Overweight Rating on Pacira Pharmaceuticals (PCRX)
Jul 3, 2024 06:42AM H.C. Wainwright Reiterates Buy Rating on Pacira Pharmaceuticals (PCRX)
Jul 3, 2024 04:03AM Barclays Downgrades Pacira Pharmaceuticals (PCRX) to Equalweight
Jul 2, 2024 11:45AM RBC Capital on Pacira Pharmaceuticals (PCRX): 'regulatory approval of the generic form is just one piece of a larger puzzle'
Jul 2, 2024 11:40AM Truist Securities Defending Pacira Pharmaceuticals (PCRX): 'Knee Jerk Reaction Overdone As We See Limited Path For Generic To Launch Despite Approval'
Jul 2, 2024 11:02AM Pacira BioSciences (PCRX): Patent Infringement Suit vs eVenus is Still Pending
Jun 13, 2024 11:57AM Jefferies Reiterates Buy Rating on Pacira Pharmaceuticals (PCRX)
View More Recent Stories